The Australian Government is now in caretaker period. During this time, updates on this website will be published in accordance with the Guidance on Caretaker Conventions, until after the election.
2688 results found
Haemolytic disease of the fetus and newborn (HDFN, also known as Rh Disease) can occur during pregnancy when a pregnant woman’s immune system produces antibodies that attack their fetus’ red blood cells (RBCs). Once a major cause of fetal and newborn mortality, today HDFN is almost non-existent in Australia due to routine antenatal blood grouping and antibody screening, and the use of prophylactic Rh D immunoglobulin and appropriate clinical management of mother and baby. Guidelines, initially produced by NHMRC on behalf of the Department of Health and Ageing, have assisted with translation of the research on Rh D antibody screening and Rh D immunoglobin into clinical practice.
For the review of the evidence for dietary guidance for older Australians.Published in June 2024.
The Water Quality Advisory Committee provides expert advice on drinking water quality and public health.
More than 400,000 Australians are living with dementia. It is Australia's second overall leading cause of burden of disease in injury, behind coronary heart disease.1 A long-term approach to the diagnosis and treatment of dementia is essential for Australia's social and economic wellbeing.
Research Excellence: Advancing health equity of the Aboriginal and Torres Strait Islander population
Associate Professor Odette Pearson is of Eastern Yalanji and Torres Strait Islander descent and coleads the Aboriginal Health Equity Theme, South Australian Health and Medical Research Institute. Her research focus is improving chronic disease and ageing outcomes of Aboriginal and Torres Strait Islander peoples through policy and guideline development and implementing and evaluating real world health and social interventions. Aboriginal leadership, governance and community and cross sector partnerships are foundations of her research. A/Prof Pearson has received the Lowitja Institute Patricia Anderson Leader in Aboriginal Research (2023), UniSA Alumini Award for Research in Aboriginal Health (2022) and The Diane Ranck, SAHMRI award for Leadership in Research (2022).
NHMRC is serious about preventing, detecting and responding to fraud and corruption and is committed to high ethical, moral and legal standards. A key focus of this framework is to raise awareness of fraud and corruption among NHMRC employees and other people who deal with NHMRC, and to assist in the prevention, detection and reporting of suspected fraud and corrupt conduct.
Neurodegenerative diseases such as Alzheimer’s, Motor Neurone and Parkinson’s disease affect millions of people around the world and place an enormous burden on the Australian healthcare system.
NHMRC takes all research integrity matters very seriously. All research we fund is required to comply with the Australian Code for the Responsible Conduct of Research, 2018 (the Code).
Professor Patrick Sexton is the Professor of Pharmacology at the Monash Institute of Pharmaceutical Sciences and is the Director at the ARC Centre for Cryo-electron Microscopy of Membrane Proteins. Professor Sexton is a leader in progressing our understanding of G protein-coupled receptors (GPCRs), particularly allosteric modulation and biased agonism, and applying cryo-EM to study structure and dynamics of GPCRs. He is a Clarivate Analytics highly cited researcher and an elected Fellow of the British Pharmacological Society (BPS). Professor Sexton is also the co-founder of Septerna Inc and DACRA Tx and has been the recipient of many awards for his scientific contributions that have had major impacts on biological chemistry research.
The NHMRC Corporate Plan 2024-25 presents our strategy for building a healthy Australia, across the strategic themes (purposes) of investment, translation and integrity of health and medical research. The plan also includes our strategic and health priorities, as well as our key activities planned for 2024–25 and over the next few years. The plan describes the operating context in which we work and outlines our performance criteria and targets for the next 4 years.
Aboriginal and Torres Strait Islander health evidence-practice policy gap reports. An evidence-practice/policy gap is the difference between what is known from the best available research evidence and what is practised in reality (through delivery of medical care or drafting of policies or guidelines).